The role and mechanism of CLEC7A in regulating PD-L1 to promote ovarian cancer growth

Objective To elucidate the role of C-type lectin domain family 7 member A （CLEC7A） in high-grade serous ovarian carcinoma （HGSOC） and its underlying mechanisms. Methods Using the Cancer Genome Atlas-Ovarian Cancer （CGA-OV） dataset， combined with transcriptional regulatory network analysis and master...

Full description

Bibliographic Details
Published in:	Xin yixue
Main Author:	CHEN Yao, SUN Sibai, XU Jun, HE Jie
Format:	Article
Language:	Chinese
Published:	Editorial Office of Journal of New Medicine 2025-04-01
Subjects:	clec7a\|high-grade serous ovarian carcinoma\|pd-l1\|jak/stat3 pathway\|tumor immunity
Online Access:	https://www.xinyixue.cn/fileup/0253-9802/PDF/1745385757034-844947774.pdf

Similar Items

SPIB Knockdown Inhibits the Immune Escape of Ovarian Cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway
by: Wenfei Gu, et al.
Published: (2023-09-01)

Immunoexpression of p53 and p16 in Low and High-grade Serous Ovarian Cancer: A Cross-sectional Study
by: Ranajit Mandal, et al.
Published: (2023-11-01)

A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
by: Kristýna Němejcová, et al.
Published: (2023-02-01)

CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma
by: Jinchao Wang, et al.
Published: (2024-05-01)

Clec7a drives gut fungus-mediated host lipid deposition
by: Jie Ma, et al.
Published: (2023-11-01)

Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis
by: Ye-Min Wang, et al.
Published: (2023-08-01)

CLEC3A Promotes Immune Evasion and Tumor Progression by Enhancing PD-L1 Stability to Weaken T Cell Cytotoxicity in Luminal Breast Cancer
by: Chen C, et al.
Published: (2025-10-01)

Risk Factors for Recurrence in Serous Borderline Ovarian Tumors and Early-Stage Low-Grade Serous Ovarian Carcinoma
by: Jingjing Zhang, et al.
Published: (2025-04-01)

Molecular Analysis of High-Grade Serous Ovarian Carcinoma Exhibiting Low-Grade Serous Carcinoma and Serous Borderline Tumor
by: Kosuke Kanno, et al.
Published: (2024-08-01)

Giant Ovarian Tumor
by: Tomasz Kluz, et al.
Published: (2023-10-01)

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma
by: Teitur Sævarsson, et al.
Published: (2024-12-01)

Roles of the CLEC-2–podoplanin interaction in tumor progression
by: Katsue Suzuki-Inoue
Published: (2018-11-01)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
by: Angel Garcia-Diaz, et al.
Published: (2017-05-01)

Clec7a Worsens Long‐Term Outcomes after Ischemic Stroke by Aggravating Microglia‐Mediated Synapse Elimination
by: Hanxi Wan, et al.
Published: (2024-09-01)

Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer
by: Jung Mi Byun, et al.
Published: (2023-01-01)

Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor
by: Jess Durbin, et al.
Published: (2024-12-01)

CLEC7A Knockdown Alleviates Ischemic Stroke by Inhibiting Pyroptosis and Microglia Activation
by: Wei Li, et al.
Published: (2024-12-01)

VGLL3 expression is associated with macrophage infiltration and predicts poor prognosis in epithelial ovarian cancer
by: Razaul Haque, et al.
Published: (2023-06-01)

Morphological basics of ovarian tumor histogenesis
by: F. V. Novikov, et al.
Published: (2020-06-01)

PD-1/PD-L1 inhibitor treatment associated with cardiotoxicity regulated by macrophage polarization and SOCS3/JAK/STAT3 signaling pathway
by: Jiding Fu, et al.
Published: (2025-04-01)

Spi1 aggravates neuropathic pain by modulating Clec7a-mediated neuroinflammation and microglial phagocytosis
by: Yin Xu, et al.
Published: (2025-07-01)

Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer
by: Angel Chao, et al.
Published: (2023-10-01)

Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis
by: Jeongwan Kang, et al.
Published: (2023-10-01)

HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma
by: Hongxia Cheng, et al.
Published: (2023-12-01)

Editorial: Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes
by: Robert L. Hollis, et al.
Published: (2024-12-01)

Correlation of CLEC1B haplotypes with plasma levels of soluble CLEC-2 in healthy individuals
by: Mani Etemad, et al.
Published: (2021-11-01)

Cytoplasmic HMGB1 promotes the activation of JAK2-STAT3 signaling and PD-L1 expression in breast cancer
by: Ju-Young Han, et al.
Published: (2025-05-01)

IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion
by: Leilei Zhao, et al.
Published: (2024-02-01)

Solitary Pancreatic Metastasis from an Ovarian Carcinoma: A Diagnostic Perplexity
by: Arti Agarwal, et al.
Published: (2024-04-01)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
by: Dinoop Ravindran Menon, et al.
Published: (2021-10-01)

NMR-based serum metabolomics in patients with low-differentiated serous ovarian cancer
by: Mateusz M. Klimek, et al.
Published: (2025-06-01)

Exploring the effects of paclitaxel-loaded zein nanoparticles on human ovarian carcinoma cells
by: Stefania Scicchitano, et al.
Published: (2025-03-01)

Microsatellite Instability Status and Programmed Death Cell Ligand 1 Expression in Serous Ovarian Tumors
by: Gizem TEOMAN, et al.
Published: (2025-07-01)

Tumor-infiltrating lymphocytes are the key determinants of pathological features associated with pathogenic BRCA variants in high-grade serous ovarian carcinoma
by: Dang H. Nguyen-Phan, et al.
Published: (2025-06-01)

Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis
by: Moayed Ibrahim, et al.
Published: (2024-09-01)

Single-cell RNA sequencing reveals the change in cytotoxic NK/T cells, epithelial cells and myeloid cells of the tumor microenvironment of high-grade serous ovarian carcinoma
by: Lingnan Meng, et al.
Published: (2024-09-01)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
by: Michalis Liontos, et al.
Published: (2021-03-01)

Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis
by: Angela Santoro, et al.
Published: (2022-03-01)

Genomic and clinical insights into ovarian cancer: subtype-specific alterations and predictors of metastasis and relapse
by: Feng Cheng, et al.
Published: (2025-05-01)

Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression
by: Diana Luísa Almeida-Nunes, et al.
Published: (2024-09-01)